Ishida Mitsuaki, Iwai Muneo, Yoshida Keiko, Kagotani Akiko, Okabe Hidetoshi
Department of Clinical Laboratory Medicine and Division of Diagnostic Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Oncol Lett. 2014 Jan;7(1):65-68. doi: 10.3892/ol.2013.1669. Epub 2013 Nov 7.
Signet-ring cell melanoma is an extremely rare variant of malignant melanoma. A 68-year-old male presented with a black nodule on the left thigh. Histopathological examination revealed proliferation of sheet-like or variable-sized nests of atypical melanocytes. Neoplastic cells showing signet-ring cell appearance, characterized by the presence of eccentrically located enlarged nuclei and abundant pale cytoplasm, were also present. Immunohistochemically, the tumor cells were positive for S-100 protein, vimentin and Melan-A. Moreover, mammalian target of rapamycin (mTOR) pathway proteins were diffusely expressed. The current case report presents the 21st reported case of signet-ring cell melanoma. Analyses of the clinicopathological features revealed that this disease commonly affects middle-aged males and the presence of metastatic signet-ring cell melanoma with an unknown primary tumor. Immunohistochemical analyses of melanocytic markers have been useful for establishing the diagnosis of this type of disease, however, HMB-45 is occasionally found to be negative. In addition, the present case report is the first to analyze the expression of mTOR pathway proteins, which are central proteins involved in carcinogenesis and its inhibitor has been proposed as a therapeutic target for various types of tumor. Therefore, the mTOR inhibitor may also be a potential candidate for the treatment of this type of tumor.
印戒细胞黑色素瘤是恶性黑色素瘤中一种极其罕见的变异类型。一名68岁男性患者左大腿出现一个黑色结节。组织病理学检查显示非典型黑素细胞呈片状或大小不一的巢状增生。肿瘤细胞还呈现印戒细胞外观,其特征为细胞核偏位增大且胞质丰富淡染。免疫组化显示,肿瘤细胞S-100蛋白、波形蛋白和Melan-A呈阳性。此外,雷帕霉素靶蛋白(mTOR)通路蛋白呈弥漫性表达。本病例报告为第21例报道的印戒细胞黑色素瘤病例。对临床病理特征的分析表明,该疾病通常累及中年男性,且存在原发肿瘤不明的转移性印戒细胞黑色素瘤。黑素细胞标志物的免疫组化分析有助于确诊此类疾病,然而,HMB-45偶尔呈阴性。此外,本病例报告首次分析了mTOR通路蛋白的表达,这些蛋白是参与致癌过程的核心蛋白,其抑制剂已被提议作为各类肿瘤的治疗靶点。因此,mTOR抑制剂也可能是治疗此类肿瘤的潜在候选药物。